dacarbazine has been researched along with lutetium lu 177 dotatate in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P | 1 |
1 other study(ies) available for dacarbazine and lutetium lu 177 dotatate
Article | Year |
---|---|
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution | 2018 |